EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of Direct-Acting Antivirals (DAAs) in Hepatitis C Virus-Associated Lymphoproliferative Disorders

Cesare Mazzaro, Riccardo Bomben iD, Laura Gragnani iD, Marcella Visentini, Paolo Agostinis, Silvia Marri iD, Anna Linda Zignego iD, Valter Gattei

Cancers · 04.08.2026 · 18 (15) · 2501

DOI: 10.3390/cancers18152501 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 04.08.2026. Verfasst von Cesare Mazzaro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis C virus (HCV) infection is a major cause of chronic hepatitis, affecting approximately 50 million people worldwide. An estimated 15–30% of individuals with chronic HCV infection progress to cirrhosis, which may subsequently develop into hepatocellular carcinoma. Beyond liver disease, HCV is associated with a broad spectrum of extrahepatic manifestations, particularly mixed cryoglobulinemia (MC) and B-cell non-Hodgkin lymphoma (B-NHL). Persistent viral infection induces chronic antigenic stimulation of B lymphocytes, a key pathogenic mechanism underlying the progression from MC to overt B-NHL. These observations have important therapeutic implications and support the use of antiviral therapy as a cornerstone of treatment. The efficacy of direct-acting antivirals (DAAs) has been well established in patients with HCV-related MC and cryoglobulinemic vasculitis. Several studies have shown that DAAs achieve sustained virologic response rates exceeding 90%, often approaching 100% in contemporary cohorts. Viral eradication is frequently associated with clinical and immunological improvement, as well as regression of cryoglobulinemia. Encouraging outcomes have also been reported in patients with HCV-associated indolent B-NHL, particularly marginal zone lymphoma, although confirmation in larger studies with longer follow-up is needed. In patients with HCV-positive aggressive lymphomas, DAAs have been safely administered in combination with immunochemotherapy, yielding promising results. This review summarizes the current evidence on HCV-associated MC and B-NHL and discusses the impact of DAA therapy on the clinical course and management of these disorders.

Schlagwörter

Stichwörter der Autor:innen

B-cell non-Hodgkin lymphomacryoglobulinemic vasculitisdirect-acting antiviral agentsextrahepatic manifestationshepatitis C virusmixed cryoglobulinemiarituximab

Autor:innen und Institutionen

  • Clinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
  • Department of Translational Research and New Surgical and Medical Technologies, University of Pisa, 56126 Pisa, Italy.
  • Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, Italy.
  • Department of Internal Medicine, Hospital of Tolmezzo, 33028 Tolmezzo, Italy.
  • Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.

ORCID-Profile: Riccardo Bomben, Laura Gragnani, Silvia Marri, Anna Linda Zignego

Förderung

  • Italian Ministry of Health

Zitieren

APA

Mazzaro, C., Bomben, R., Gragnani, L., Visentini, M., Agostinis, P., Marri, S., Zignego, A. L., & Gattei, V. (2026). The Role of Direct-Acting Antivirals (DAAs) in Hepatitis C Virus-Associated Lymphoproliferative Disorders. Cancers, 18(15), 2501. https://doi.org/10.3390/cancers18152501

Vancouver

Mazzaro C, Bomben R, Gragnani L, Visentini M, Agostinis P, Marri S, et al. The Role of Direct-Acting Antivirals (DAAs) in Hepatitis C Virus-Associated Lymphoproliferative Disorders. Cancers. 2026;18(15):2501. doi:10.3390/cancers18152501

BibTeX
@article{Mazzaro2026,
  author = {Mazzaro, Cesare and Bomben, Riccardo and Gragnani, Laura and Visentini, Marcella and Agostinis, Paolo and Marri, Silvia and Zignego, Anna Linda and Gattei, Valter},
  title = {The Role of Direct-Acting Antivirals (DAAs) in Hepatitis C Virus-Associated Lymphoproliferative Disorders},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {15},
  pages = {2501},
  doi = {10.3390/cancers18152501}
}
Kostenlos starten →